Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$118000.0.

  • Ocular Therapeutix's Change in Receivables fell 10548.07% to -$118000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 million, marking a year-over-year decrease of 12799.16%. This contributed to the annual value of -$1.7 million for FY2025, which is 12799.16% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Change in Receivables of -$118000.0 as of Q4 2025, which was down 10548.07% from $356000.0 recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Change in Receivables ranged from a high of $6.2 million in Q2 2023 and a low of -$7.2 million during Q1 2025
  • For the 5-year period, Ocular Therapeutix's Change in Receivables averaged around $919900.0, with its median value being $1.1 million (2021).
  • Over the last 5 years, Ocular Therapeutix's Change in Receivables had its largest YoY gain of 1176666.67% in 2025, and its largest YoY loss of 205286.1% in 2025.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Change in Receivables stood at $1.6 million in 2021, then decreased by 3.79% to $1.5 million in 2022, then skyrocketed by 70.06% to $2.6 million in 2023, then dropped by 16.87% to $2.2 million in 2024, then tumbled by 105.48% to -$118000.0 in 2025.
  • Its Change in Receivables stands at -$118000.0 for Q4 2025, versus $356000.0 for Q3 2025 and $5.2 million for Q2 2025.